Effects of behavioral sleep extension on Alzheimers disease relevant blood biomarkers and cognitive performance

项目总结/摘要 数十年的实验和流行病学研究将睡眠时间短与不良心脏代谢联系起来。 健康此外，新兴的研究指出，直接的生物机制将短睡眠时间与 认知能力下降和老年痴呆症尽管几十年来都有证据证明睡眠不足的有害影响 虽然阿尔茨海默病的发病时间很长，但很少有研究试图通过延长阿尔茨海默病的发病时间来改善风险或改变阿尔茨海默病的发展轨迹。 睡吧睡眠延长干预有望改善心脏代谢疾病（CMD）风险，认知 和生活质量。到目前为止，一些小型研究已经证明了睡眠的短期改善， CMD风险，如血压和血糖控制。然而，现有的成人研究尚未解决 睡眠延长干预是否会影响认知能力和阿尔茨海默病的生物标志物 风险本申请的目的是扩展我们的母研究的目的，包括检查 我们的随机行为睡眠延长干预对阿尔茨海默病相关的 生物标志物（血液代谢组学）和认知表现测量。在我们的父母研究中，我们 进行一项随机对照试验，以测试我们的行为睡眠延长干预措施， 健康教育对照组对高血压前期/I期成人睡眠和CMD危险性影响 高血压为期12个月的研究包括干预期（第1-8周，每周干预一次）， 维持期（2-6个月，每月干预）和随访期（无干预）。主 母研究的结局是睡眠时间，主要次要结局是24小时动态血液 血压监测，这使我们能够评估白天和夜间的血压。的设计 这项母体研究将使我们能够检查睡眠的急性（8周）和持续（12个月）变化 持续时间，BP和重要的心理，行为和生理介质，包括自我报告 嗜睡、BMI、饮食、体力活动、血糖控制和炎症。这张老年痴呆症的收据 疾病补充将使我们能够扩大我们的母研究的范围，以检查我们的影响， 睡眠延长干预对血液生物标志物和认知能力的影响。成功完成 这项研究将提供关于行为睡眠延长对重要的 将睡眠延长纳入CMD所需的健康和生活质量指标， 阿尔茨海默病风险干预措施。完成本补充材料将确定潜在的生化 对睡眠延长做出反应的途径和行为表型。鉴定这些生物和 对睡眠延长的反应的行为标志物有可能导致生物标志物的鉴定， 降低阿尔茨海默病风险的新靶点。

PROJECT SUMMARY/ABSTRACT Decades of experimental and epidemiologic research link short sleep duration to adverse cardiometabolic health. Furthermore, emerging research points to direct biological mechanisms linking short sleep duration to cognitive decline and Alzheimer’s disease. Despite decades documenting the deleterious effects of short sleep duration, few studies have sought to improve risk or modify Alzheimer’s disease trajectories by extending sleep. Sleep extension interventions hold promise to improve cardiometabolic disease (CMD) risk, cognition and quality of life. To date, several small studies have demonstrated short term improvements in sleep and CMD risk such as blood pressure and glycemic control. However, existing studies in adults have not addressed whether sleep extension interventions impact cognitive performance and biomarkers of Alzheimer’s Disease risk. The goal of this application is to extend the aims of our parent study to include an examination of the impact of our randomized behavioral sleep extension intervention on Alzheimer’s related biomarkers (blood metabolomics) and cognitive performance measures. In our parent study, we are conducting a randomized controlled trial to test our behavioral sleep extension intervention compared to a health education control group on sleep and CMD risk among adults with prehypertension/stage I hypertension. The 12-month study includes an intervention period (weeks 1-8, weekly intervention), maintenance period (months 2-6, monthly intervention) and follow-up period (no intervention). The primary outcome for the parent study is sleep duration and the main secondary outcome is 24-h ambulatory blood pressure monitoring, which allows us to evaluate both daytime and nighttime blood pressures. The design of this parent study will allow us to examine the acute (8 week) and sustained (12 month) changes in sleep duration, BP and important psychological, behavioral and physiological mediators including self-reported sleepiness, BMI, diet, physical activity, glycemic control and inflammation. The receipt of this Alzheimer’s disease supplement will allow us to extend the scope of our parent study to examine the effects of our sleep extension intervention on blood biomarkers and cognitive performance. Successful completion of this study will provide critical information about the impact of behavioral sleep extension on important measures of health and quality of life needed to incorporate sleep extension into CMD, and potentially Alzheimer’s disease risk interventions. Completion of this supplement will identify potential biochemical pathways and behavioral phenotypes that respond to sleep extension. Identification of these biological and behavioral markers of response to sleep extension has the potential to lead to identification of biomarkers and novel targets to reduce Alzheimer’s Disease risk.